A pharmaceutical manufacturer receives notification that Health Canada will conduct a GMP inspection of their facility in six weeks. The quality director’s first instinct is to schedule a document review. But document review alone is not inspection preparation. Health Canada inspectors assess not just whether documents exist, but whether the quality system described in those documents is actually functioning as written — and whether the people responsible for running it understand it.
This article is for quality and regulatory teams at pharmaceutical manufacturers, CMOs, and CROs preparing for a Health Canada GMP inspection. We outline the key areas inspectors focus on, the preparation activities that make the most difference, and how to respond effectively when observations are issued.
Health Canada conducts GMP inspections of drug establishments under the authority of the Food and Drugs Act and the Food and Drug Regulations. Inspections are conducted by inspectors from the Health Products and Food Branch (HPFB) Inspectorate. The inspection program is risk-based — the frequency and depth of inspection depend on the establishment’s compliance history, the risk profile of the activities performed, and the drug classes involved.
Inspections may be:
For most established manufacturers, routine inspections are the most common type. The notification period for routine inspections varies and may be short. Facilities should maintain a state of inspection readiness at all times rather than treating inspection preparation as a periodic event.
Based on publicly available Health Canada inspection guidance and our experience supporting facilities through the inspection process, the following areas receive consistent attention:
Data integrity is one of the most significant areas of focus in current GMP inspections globally, and Health Canada is no exception. Inspectors assess whether:
Data integrity findings are among the most serious that Health Canada can issue, because they call into question the reliability of all data generated at the facility. Preparation in this area should include a thorough review of all computerized systems and their audit trail configurations.
Health Canada inspectors review OOS investigation records closely. They assess whether:
A common finding is the invalidation of OOS results based on insufficient evidence — for example, invalidating a result because a retest passes, without identifying the specific laboratory error that caused the original OOS. Inspectors will review the complete OOS file, including the original data, the investigation narrative, and the conclusion.
Change control is a systemic area — inspectors assess not just individual change records but whether the change control system is functioning as intended. They look for:
Preparation should include a review of recent changes to identify any that may have been implemented outside the change control system or that may require additional documentation.
Inspectors assess whether critical processes, cleaning procedures, and analytical methods are validated and whether the validation status is current. Key questions include:
Validation master plans and validation status summaries are useful tools for demonstrating the overall validation status of the facility to an inspector.
Inspectors assess whether personnel are trained on the procedures relevant to their roles and whether training records are current. They may ask personnel directly about procedures — a person who cannot describe the procedure they are supposed to follow, or who describes a practice that differs from the written procedure, is a finding.
Preparation should include a review of training records for completeness and a check that procedures have been updated to reflect current practice (not the reverse — updating practice to match outdated procedures is not sufficient).
Inspectors assess whether suppliers of critical materials — including APIs, excipients, and primary packaging — have been qualified and whether the qualification is current. For contract laboratories, inspectors may ask to see audit records and quality agreements.
The following activities are most effective in the weeks before an inspection:
Mock inspection: Conduct an internal mock inspection using the same areas of focus as a Health Canada inspection. Use personnel who were not involved in preparing the documents being reviewed. Document findings and implement corrective actions before the actual inspection.
Document review: Confirm that all SOPs are current, approved, and reflect actual practice. Review recent batch records, OOS investigations, change control records, and deviation reports for completeness and consistency.
System walk-through: Walk through the facility with the inspection team to identify any visible compliance issues — labelling, cleanliness, equipment status, environmental monitoring records.
Personnel briefing: Brief all personnel who may interact with inspectors on their roles during the inspection, the importance of answering questions accurately and within their knowledge, and the procedure for escalating questions they cannot answer.
Document control check: Confirm that all documents are version-controlled, that obsolete versions have been removed from use, and that the document management system is functioning correctly.
At the conclusion of the inspection, Health Canada inspectors will communicate their observations. Observations are classified by severity, and the facility is required to respond within a specified timeframe.
Effective responses:
Responses that simply describe what was done to fix the immediate issue, without addressing the root cause, are likely to be found insufficient. Inspectors expect that the facility has understood why the issue occurred and has taken steps to prevent recurrence.
Data Integrity
OOS Investigations
Change Control
Validation
Training
Supplier Qualification
General
Health Canada GMP inspections are a normal part of operating a licensed drug establishment. Requirements may vary depending on the establishment type, the drug classes involved, and the inspection type. We recommend maintaining a state of continuous inspection readiness rather than treating preparation as a periodic exercise.
At Androxa, we support pharmaceutical manufacturers and CMOs with inspection readiness assessments, mock inspections, and quality system gap analyses. Contact our team at testing-lab.ca to discuss your inspection preparation needs.